tiprankstipranks
Trending News
More News >
Immunome (IMNM)
NASDAQ:IMNM
US Market

Immunome (IMNM) Stock Statistics & Valuation Metrics

Compare
301 Followers

Total Valuation

Immunome has a market cap or net worth of $800.51M. The enterprise value is $6.77M.
Market Cap$800.51M
Enterprise Value$6.77M

Share Statistics

Immunome has 87,012,330 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding87,012,330
Owned by Insiders1.62%
Owned by Institutions41.54%

Financial Efficiency

Immunome’s return on equity (ROE) is -1.62 and return on invested capital (ROIC) is -164.41%.
Return on Equity (ROE)-1.62
Return on Assets (ROA)-1.22
Return on Invested Capital (ROIC)-164.41%
Return on Capital Employed (ROCE)-1.64
Revenue Per Employee69.02K
Profits Per Employee-2.24M
Employee Count131
Asset Turnover0.04
Inventory Turnover0.00

Valuation Ratios

The current PE Ratio of Immunome is -2.13. Immunome’s PEG ratio is -0.02.
PE Ratio-2.13
PS Ratio0.00
PB Ratio1.61
Price to Fair Value3.44
Price to FCF-0.93
Price to Operating Cash Flow-0.93
PEG Ratio-0.02

Income Statement

In the last 12 months, Immunome had revenue of 9.04M and earned -292.96M in profits. Earnings per share was -5.00.
Revenue9.04M
Gross Profit9.04M
Operating Income-305.80M
Pretax Income-292.96M
Net Income-292.96M
EBITDA-151.35M
Earnings Per Share (EPS)-5.00

Cash Flow

In the last 12 months, operating cash flow was -152.68M and capital expenditures -8.92M, giving a free cash flow of -161.60M billion.
Operating Cash Flow-152.68M
Free Cash Flow-161.60M
Free Cash Flow per Share-1.86

Dividends & Yields

Immunome pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share
Dividend Yield
Payout RatioN/A
Free Cash Flow Yield
Earnings Yield

Stock Price Statistics

Beta1.86
52-Week Price Change-30.04%
50-Day Moving Average8.12
200-Day Moving Average10.62
Relative Strength Index (RSI)56.32
Average Volume (3m)902.84K

Important Dates

Immunome upcoming earnings date is Aug 13, 2025, TBA Not Confirmed.
Last Earnings DateMay 12, 2025
Next Earnings DateAug 13, 2025
Ex-Dividend Date

Financial Position

Immunome as a current ratio of 4.08, with Debt / Equity ratio of 1.76%
Current Ratio4.08
Quick Ratio4.08
Debt to Market Cap<0.01
Net Debt to EBITDA0.92
Interest Coverage Ratio0.00

Taxes

In the past 12 months, Immunome has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00

Enterprise Valuation

Immunome EV to EBITDA ratio is -3.20, with an EV/FCF ratio of -4.10.
EV to Sales53.56
EV to EBITDA-3.20
EV to Free Cash Flow-4.10
EV to Operating Cash Flow-4.37

Balance Sheet

Immunome has $317.32M in cash and marketable securities with $4.77M in debt, giving a net cash position of -$312.55M billion.
Cash & Marketable Securities$317.32M
Total Debt$4.77M
Net Cash-$312.55M
Net Cash Per Share-$3.59
Tangible Book Value Per Share$3.09

Margins

Gross margin is 0.00%, with operating margin of -3382.37%, and net profit margin of -3240.38%.
Gross Margin0.00%
Operating Margin-3382.37%
Pretax Margin-3240.38%
Net Profit Margin-3240.38%
EBITDA Margin-1674.08%
EBIT Margin-1697.33%

Analyst Forecast

The average price target for Immunome is $27.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$27.00
Price Target Upside193.48% Upside
Analyst ConsensusStrong Buy
Analyst Count7
Revenue Growth Forecast-13.76%
EPS Growth Forecast57.73%

Scores

Smart Score9
AI Score49
What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis